Biotron Limited · ASX:BIT
Biotron — Shareholder Meeting (November 2020)
14 slides from Biotron's shareholder meeting presentation, Nov 19, 2020
Slide 1: Biotron Limited Annual General Meeting
BIOTRON LIMITED (ASX:BIT) Annual General Meeting 19 November 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Key Achievements 2019/2020 FY
Key Achievements 2019/2020 FY • Reported positive results from the Phase 2 HIV-1 clinical trial of BIT225 • Presented key data on BIT225 at two international meetings • Publication of data in peer-reviewed, prestigious international journal • Filed new patent applications based on Phase 2 data • Set
Slide 4: Key Achievements 2019/2020 FY (cont)
Key Achievements 2019/2020 FY (cont) • Expanded antiviral screening program to include SARS-CoV-2, the causative agent of COVID-19 • Identified a series of Biotron compounds with in vitro activity against SARS-CoV-2 • Continued to make good progress with promising Hepatitis B Virus (HBV) program • R
Slide 5: Coronavirus
Coronavirus • Biotron’s core expertise is designing drugs to target key viral proteins called viroporins that are found on a range of different viruses • Biotron has had a long-standing interest in Coronaviruses (CoVs) since SARS-1 outbreak • Biotron researchers were first to identify and report on
Slide 6: SARS-CoV-2
SARS-CoV-2 • Reinstated and expanded Biotron’s coronavirus program to cover SARS-CoV-2 in response to the COVID-19 pandemic • Since the COVID-19 outbreak Biotron has been screening its compounds for activity against SARS-CoV-2 • Identified several that inhibit growth of SARS-CoV-2 (Refer BIT ASX ann
Slide 7: HIV-1 Eradication
HIV-1 Eradication Why is HIV-1 eradication necessary? • Current antiretroviral drugs (ART) do not eradicate the virus • Long-term health implications eg. HAND, immune activation, increase in malignancies and chronic diseases, drug-drug interactions • Major burden on healthcare systems Significant in
Slide 8: HIV Treatment Gaps
HIV Treatment Gaps What has been achieved Where gaps remain • Durable and potent antiretroviral therapy • ART is not curative, latent viral reservoirs remain (ART) and reactivate • Viral suppression possible through • Immune reconstitution is only partial and continuous, lifelong ART accompanied by
Slide 9: BIT225 and HIV-1
BIT225 and HIV-1 • Untreated HIV is associated with extreme levels of inflammation and immune activation – ART helps, but does not return inflammation and activation levels to normal • With modern ART, the next challenge is less about killing the virus, and more about the immune response • BIT225 co
Slide 10: BIT225 and HIV-1 – Positioning Potential
BIT225 and HIV-1 – Positioning Potential • A safe and effective agent that in conjunction with ART reduces inflammation and leads to fewer HIV comorbidities, improved health and lessened healthcare costs • A safe and effective agent that in conjunction with ART leads to increased immune system recog
Slide 11: Hepatitis B Virus
Hepatitis B Virus • ~300 million worldwide chronically infected with HBV • Increased risk of significant liver disease, including liver failure and cancer • HBV causes up to 80% of liver cancers • 5 year survival of 15% • >780,000 die every year • as a consequence of HBV infection • Current treatmen
Slide 12: Biotron HBV Program
Biotron HBV Program • Biotron has a portfolio of novel small molecule compounds with good activity against HBV • Extensive package of preclinical in vitro data includes evidence of reduction in cccDNA, HBsAg, and other relevant HBV markers • Biotron compounds have a unique mechanism of action with i
Slide 13: Outlook for 2020/2021 FY
Outlook for 2020/2021 FY • HIV-1 program is the prime focus • Conferring with KOLs/advisory group to map out details of BIT225-010 trial • Progressing discussions with potential partners • Continuing screening to identify lead anti-SARS-CoV-2 compound(s) to progress to next stage of development • He
Slide 14: Biotron Limited (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au